Levocetirizine
Brand names: Xyzal · Active ingredient: Levocetirizine Dihydrochloride
In short: Levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.
What is Levocetirizine used for?
Levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.
Levocetirizine dosage
Levocetirizine dihydrochloride is available as 5 mg breakable (scored) tablets, allowing for the administration of 2.5 mg, if needed. Levocetirizine dihydrochloride tablets can be taken without regard to food consumption.
Adults and Children 12 Years of Age and Older
The recommended dose of levocetirizine dihydrochloride is 5 mg (1 tablet) once daily in the evening. Some patients may be adequately controlled by 2.5 mg (1/2 tablet) once daily in the evening.
Children 6 to 11 Years of Age
The recommended dose of levocetirizine dihydrochloride is 2.5 mg (1/2 tablet) once daily in the evening. The 2.5 mg dose should not be exceeded because the systemic exposure with 5 mg is approximately twice that of adults
.
Dose Adjustment for Renal and Hepatic Impairment
In adults and children 12 years of age and older with:
Mild renal impairment (creatinine clearance [CL
CR] = 50 to 80 mL/min): a dose of 2.5 mg once daily is recommended;
Moderate renal impairment (CL
CR= 30 to 50 mL/min): a dose of 2.5 mg once every other day is recommended;
Severe renal impairment (CL
CR= 10 to 30 mL/min): a dose of 2.5 mg twice weekly (administered once every 3 to 4 days) is recommended;
End-stage renal disease patients (CL
CR<10 mL/min) and patients undergoing hemodialysis should not receive levocetirizine dihydrochloride tablets.
No dose adjustment is needed in patients with solely hepatic impairment. In patients with both hepatic impairment and renal impairment, adjustment of the dose is recommended.
How to take Levocetirizine — instructions & advice from the label
Somnolence
Caution patients against engaging in hazardous occupations requiring complete mental alertness, and motor coordination such as operating machinery or driving a motor vehicle after ingestion of levocetirizine dihydrochloride tablets
.
Concomitant Use of Alcohol and other Central Nervous System Depressants
Instruct patients to avoid concurrent use of levocetirizine dihydrochloride tablets with alcohol or other central nervous system depressants because additional reduction in mental alertness may occur
.
Risk of New Onset Pruritus After Discontinuation of Levocetirizine Dihydrochloride Tablets
Inform patients pruritus has occurred within a few days of discontinuing levocetirizine dihydrochloride among patients who used levocetirizine dihydrochloride long-term (e.g., few months to years). Pruritus may improve with restarting or tapering levocetirizine dihydrochloride
. Advise patients to seek medical advice if pruritus occurs.
Dosing of Levocetirizine Dihydrochloride Tablets
Do not exceed the recommended daily dose in adults and adolescents 12 years of age and older of 5 mg once daily in the evening. …
Warnings & precautions
Do not take this medicine if: The use of levocetirizine dihydrochloride tablets is contraindicated in:
Patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. Observed reactions range from urticaria to anaphylaxis
.
Patients with end-stage renal disease (CL
CR< 10 mL/min) and patients undergoing hemodialysis.
Children 6 months to 11 years of age with impaired renal function.
In clinical trials the occurrence of somnolence, fatigue, and asthenia has been reported in some patients under therapy with levocetirizine dihydrochloride. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness, and motor coordination such as operating machinery or driving a motor vehicle after ingestion of levocetirizine dihydrochloride. Concurrent use of levocetirizine dihydrochloride with alcohol or other central nervous system depressants should be avoided because additional reductions in alertness and additional impairment of central nervous system performance may occur.
Urinary retention has been reported postmarketing with levocetirizine dihydrochloride. Levocetirizine dihydrochloride should be used with caution in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as levocetirizine dihydrochloride may increase the risk of urinary retention. Discontinue levocetirizine dihydrochloride if urinary retention occurs.
Cases of pruritus after discontinuation of levocetirizine dihydrochloride have been reported in the postmarketing setting in patients where pruritus was not present before initiation of levocetirizine dihydrochloride. Pruritus occurred within a few days of discontinuing levocetirizine dihydrochloride among patients who used levocetirizine dihydrochloride long-term (e.g., few months to years). …
Levocetirizine side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Somnolence
Urinary Retention
Risk of New Onset Pruritus After Discontinuation of Levocetirizine Dihydrochloride
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data described below reflect exposure to levocetirizine dihydrochloride in 2708 patients with allergic rhinitis or chronic idiopathic urticaria in 14 controlled clinical trials of 1 week to 6 months duration.
The short-term (exposure up to 6 weeks) safety data for adults and adolescents are based upon eight clinical trials in which 1896 patients (825 males and 1071 females aged 12 years and older) were treated with levocetirizine dihydrochloride 2.5, 5, or 10 mg once daily in the evening. …
Drug interactions
In vitrodata indicate that levocetirizine is unlikely to produce pharmacokinetic interactions through inhibition or induction of liver drug-metabolizing enzymes. No
in vivodrug-drug interaction studies have been performed with levocetirizine. Drug interaction studies have been performed with racemic cetirizine.
Pharmacokinetic interaction studies performed with racemic cetirizine demonstrated that cetirizine did not interact with antipyrine, pseudoephedrine, erythromycin, azithromycin, ketoconazole, and cimetidine. There was a small decrease (~ 16%) in the clearance of cetirizine caused by a 400 mg dose of theophylline. It is possible that higher theophylline doses could have a greater effect.
Ritonavir increased the plasma AUC of cetirizine by about 42% accompanied by an increase in half-life (53%) and a decrease in clearance (29%) of cetirizine. The disposition of ritonavir was not altered by concomitant cetirizine administration.
About this medicine
Levocetirizine dihydrochloride, USP, the active component of Levocetirizine Dihydrochloride Tablets USP, is an orally active H
1-receptor antagonist. The chemical name is R-(+)-2-[2-[4-[(4-chlorophenyl) phenyl methyl] piperazin-1-yl] ethoxy] acetic acid dihydrochloride. Levocetirizine dihydrochloride, USP is the R enantiomer of cetirizine hydrochloride, a racemic compound with antihistaminic properties. The chemical structure is shown below:
C
21H
25ClN
2O
3•2HCl M.W. 461.8
Levocetirizine dihydrochloride, USP is a white or almost white powder and is freely soluble in water, practically insoluble in acetone and in methylene chloride. Levocetirizine dihydrochloride tablets USP, 5 mg are formulated as immediate-release white to off-white, film-coated, oval-shaped, scored tablets for oral administration. One side of the tablet is scored in half and debossed with the number "9" on one side of the score and "3" on the other. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 344ba2d6-4e17-4cef-bd7b-248fbb1af3b6. Read the full official label on DailyMed.
Related medicines
Doxycycline Adalimumab Ketoconazole Cyclosporine Tretinoin Brimonidine Dupilumab Isotretinoin